Pharma Giant Johnson & Johnson Asks FDA To Approve Esketamine Nasal Spray For Treatment-Resistant Depression
Portfolio Pulse from Nina Zdinjak
Johnson & Johnson (NYSE: JNJ) has requested FDA approval for its esketamine nasal spray, Spravato, as a monotherapy for treatment-resistant depression (TRD) in adults. If approved, it will be the first monotherapy for TRD. The application is backed by positive Phase 4 study results. Spravato sales have shown nearly 100% growth year-over-year.
July 23, 2024 | 5:20 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Johnson & Johnson has applied for FDA approval for its esketamine nasal spray, Spravato, as a monotherapy for treatment-resistant depression. The application is supported by positive Phase 4 study results and strong sales growth.
The FDA approval for Spravato as a monotherapy could significantly boost J&J's revenue and market position in the treatment-resistant depression segment. The strong Phase 4 results and nearly 100% year-over-year sales growth further support a positive outlook.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100